脑血管疾病是神经系统的常见病及多发病,其发病率为(100～300)/10万,患病率为(500～740)/10万,死亡率为(50～100)/10万,约占所有疾病死亡人数的10％,是目前人类疾病的三大死亡原因之一,存活者中50％～70％病人遗留瘫痪、失语等严重残疾,给社会和家庭带来沉重的负担。而脑梗塞约占全部脑卒中的80％。在急性脑梗塞治疗中,溶栓治疗是再灌注窗治疗时限内实现再灌注的最佳方法。但是,溶栓治疗的有效性及危险性在国际上尚无完全一致的观点,只能严格掌 Cerebrovascular disease is a common and frequently-occurring disease of the nervous system with a prevalence of (100-300) / 100,000 and a prevalence of (500-740) / 100,000 and a mortality rate of (50-100) / 100,000 , Accounting for about 10% of all disease deaths. It is one of the three major causes of death in human diseases. 50% to 70% of survivors are left with paralysis and severe disability such as aphasia, posing a heavy burden to society and families. Cerebral infarction accounts for about 80% of all strokes. In acute cerebral infarction, thrombolytic therapy is the best way to achieve reperfusion within the time frame of reperfusion window treatment. However, the effectiveness and risk of thrombolytic therapy in the world is not exactly the same point of view, only strict control